HER2选择性酪氨酸激酶抑制剂Zongertinib(BI 1810631)在HER2改变晚期/转移性实体瘤患者中的Ia期剂量递增研究
Beamion LUNG-1是一项多中心、多队列Ia/Ib期试验,Ia期评估Zongertinib在经治HER2改变实体瘤患者中的安全性/疗效。截至2024年5月23日,105例患者接受治疗,未达到最大耐受剂量,扩展推荐剂量为120 mg每日一次和240 mg每日一次。确认的总体客观缓解率为30%,非小细胞肺癌患者为35%。
要点
- Zongertinib在经治HER2改变实体瘤患者中安全性可控,未达到最大耐受剂量。
- 扩展推荐剂量为120 mg每日一次和240 mg每日一次。
- 非小细胞肺癌患者确认客观缓解率为35%,A775_G776insYVMA患者为38%。
核心结论
- Zongertinib具有可控的安全性,并在HER2改变肿瘤(包括HER2突变非小细胞肺癌)患者中显示出初步抗肿瘤活性。
研究设计与样本
- Beamion LUNG-1(NCT04886804)是一项正在进行中的多中心、多队列Ia/Ib期试验。
- Ia期评估Zongertinib每日两次(15-150 mg)或每日一次(60-360 mg)在经治各种肿瘤(包括非小细胞肺癌)患者中的给药。
- 主要终点为最大耐受剂量和剂量限制性毒性;肿瘤缓解为次要终点。
主要发现
- 截至2024年5月23日,105例患者接受治疗;最大耐受剂量评估期间发生2例剂量限制性毒性,未达到最大耐受剂量。
- 治疗相关不良事件(任何级别/≥3级)发生率分别为82%/10%;最常见包括腹泻(50%/1%)、皮疹(16%/2%)、贫血(10%/0%)、食欲下降(10%/1%)和丙氨酸转氨酶升高(10%/4%)。
- 所有剂量/肿瘤中,研究者评估的确认总体客观缓解率为30%(95% CI,23至40);中位缓解持续时间为12.7个月(95% CI,6.9至未达到)。
- 在54例非小细胞肺癌患者中,确认客观缓解率为35%(95% CI,24至49);A775_G776insYVMA患者客观缓解率为38%,既往接受过HER2靶向治疗者客观缓解率为28%。
- 在接受每日一次Zongertinib的非小细胞肺癌患者中,中位无进展生存期为17.2个月(95% CI,8.3至未达到)。
关键数值与推荐
- 扩展推荐剂量为120 mg每日一次和240 mg每日一次。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Human epidermal growth factor receptor 2 (HER2) alterations occur in many solid cancers, including non-small cell lung cancer (NSCLC). Beamion LUNG-1 (ClinicalTrials.gov identifier: NCT04886804) is assessing the safety/efficacy of zongertinib (BI 1810631), a novel HER2-selective tyrosine kinase inhibitor that spares epidermal growth factor receptor, in patients with HER2-altered solid tumors. MATERIALS AND METHODS: Beamion LUNG-1 is an ongoing multicenter, multicohort phase Ia/Ib trial. Phase Ia assessed zongertinib administered twice a day (15-150 mg) or once daily (60-360 mg) in pretreated patients with various tumors, including NSCLC. Primary end points were maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs); tumor response was a secondary end point. RESULTS: As of May 23, 2024, 105 patients were treated. Two DLTs occurred during the MTD evaluation period; MTD was not reached (NR). The recommended doses for expansion were 120 mg once daily and 240 mg once daily. Treatment-related adverse events (TRAEs; any/grade ≥3) occurred in 82%/10% of patients. The most common TRAEs (any/grade ≥3) included diarrhea (50%/1%), rash (16%/2%), anemia (10%/0%), decreased appetite (10%/1%), and increased alanine transaminase (10%/4%). The confirmed investigator-assessed overall response rate (ORR) across all doses/tumors was 30% (95% CI, 23 to 40); median duration of response was 12.7 months (95% CI, 6.9 to NR). In 54 patients with NSCLC, confirmed ORR was 35% (95% CI, 24 to 49). Activity was observed in patients with A775_G776insYVMA (ORR, 38%) and those who had received previous HER2-directed therapy (ORR, 28%). In patients with NSCLC receiving zongertinib once daily, median progression-free survival was 17.2 months (95% CI, 8.3 to NR). CONCLUSION: Zongertinib had a manageable safety profile and demonstrated preliminary antitumor activity in patients with HER2-altered tumors, including those with HER2-mutant NSCLC.
引用
- Heymach JV, Opdam F, Barve M, et al. HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study. J Clin Oncol. 2025. PMID: 40030100. doi:10.1200/JCO-24-01727
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。